>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance:

NAII +23%, (thinly traded)
TMUS +1%, (reiterates its current financial guidance and full year outlook and announces 'the strongest iPhone pre-order in Company history)

M&A news:

TBRA +575.5% (to be acquired by Allergan (AGN) for an upfront payment of $28.35/share in cash, and up to $49.84/share in Contingent Value Rights)
DTSI +21.8% (to be acquired by Tessera Technologies (TSRA) for $42.50/share)
CYH +2.8% (reports of Apollo Global (APO) discussions)

Select large pharma names showing strength: NVS +1.9%, NVO +1.7%, SNY +1.6%, AZN +1.4%, SHPG +1.1%, .

Other news:

CNAT +36% (TBRA peer, in sympathy)
WINT +27.3% (announces FDA Fast Track Designation for AEROSURF)
CANF +23.9% (announces the peer reviewed scientific journal Molecular Medicine Report has published an article detailing new data on CF102)
GALT +21.6% (TBRA peer, in sympathy)
HDP +6.6% (Hortonworks & IBM (IBM) announce the planned availability of Hortonworks Data Platform for IBM Power Systems enabling POWER8 clients )
ICPT +5.9% (TBRA peer, in sympathy)
AMPH +5.8% (to join S&P SmallCap 600)
PBYI +5.8% (confirms FDA acceptance of new drug application for PB272 )
PIR +5.1% (Alden Global discloses 9.5% active stake, details talks with management)
SRPT +5% (following 75% surge higher on FDA accelerated approval of EXONDYS 51 (eteplirsen) injection; plans to file MAA in Europe for eteplirsen by the end of the year)
TXMD +2.5% ( announces that the FDA has accepted the NDA for Yuvvexy; PDUFA of May 7, 2017 established)
HOV +1.8% (in sympathy with LEN (earnings))
CRUS +1.3% (to join the S&P MidCap 400)
RCL +0.9% (increases quarterly dividend)

Analyst comments: